Medicenna Therapeutics Q1 EPS $(0.06), Inline
Medicenna Therapeutics (TSX:MDNA) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Medicenna lost the same small amount of money per share as expected, and it's the same as last year—so nothing surprising happened. When a company meets what people predicted and stays steady, it means things are running pretty much as planned.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.